Physician profile
Simi George
NPI 1396980397
$736.93
in general payments reported to CMS, 2019-2025
18 companies · $336 in 2025
The $336 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $41.73 · 2023: $211 · 2024: $148 · 2025: $336.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $669 · Education: $25.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $669.25 |
| Education | $25.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $191.03 | 2023-2025 | Carvykti, Rybrevant, Tecvayli |
| Daiichi Sankyo INC. | $112.43 | 2023-2024 | Enhertu, Vanflyta |
| Novartis Pharmaceuticals Corporation | $73.26 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $44.64 | 2024-2025 | Enhertu |
| Merck Sharp & Dohme LLC | $32.31 | 2023-2024 | Keytruda, Lynparza |
| Celgene Corporation | $29.96 | 2025 | Opdivo |
| Seagen INC. | $25.31 | 2023 | Adcetris |
| Mirati Therapeutics, INC. | $25.14 | 2024 | Krazati |
| Lilly USA, LLC | $24.93 | 2023 | Retevmo, Jaypirca, Verzenio |
| Kite Pharma, INC. | $23.11 | 2022 | |
| Abbvie INC. | $22.91 | 2025 | |
| Caris Mpi, INC. | $22.77 | 2025 | Mi Cancer Seek |
| Genentech USA, INC. | $22.69 | 2025 | Tecentriq |
| Janssen Scientific Affairs, LLC | $18.85 | 2025 | Erleada |
| Medtronic, INC. | $18.62 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $18.42 | 2023 | |
| Beigene USA, INC. | $18.04 | 2023 | Brukinsa |
| Pharmaand Gmbh | $12.51 | 2025 | Rubraca |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Simi George listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.